Scribe Therapeutics’ IPO will support a pipeline led by a genetic medicine that represses expression of its target gene without making permanent changes. Common chronic cardiometabolic conditions are Scribe’s initial focus as the biotech works to bring genetic medicines beyond rare diseases.

The post CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO appeared first on MedCity News.